Why I believe these 3 stocks will struggle in 2017

These three companies are in danger of generating losses for investors next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2017 is just around the corner and City analysts are picking their top stocks for the 12 months ahead. As well as the stocks I’m betting on for 2017, there are some companies I want to avoid next year as headwinds for these firms grow.

Indeed, I believe shares in Reckitt Benckiser (LSE: RB) will come under pressure next year as so-called ‘bond proxy’ stocks continue to fall out of favour with investors. 

Bond proxies are equities that have become an alternative to bonds as interest rates on bonds plunge into negative territory. Defensive companies such as Reckitt are prime proxies as their cash flows are considered safe, helping long-term dividend sustainability. However, as bond yields around the world are now pushing higher, these bond proxies are becoming less popular. 

It’s easy to see why. Yes, these are high-quality businesses, but the reach for yield has pushed their valuations up to record levels. Shares in Reckitt currently trade at a forward P/E of 22.9, down from last year’s 23.9 but still far above peer Unilever’s 19.7. I expect Reckitt’s shares to fall next year as investors rebalance away from bond proxies back towards bonds.

Revenues falling 

AstraZeneca (LSE: AZN) is another company I’m avoiding for 2017. This year, Astra’s most successful drug Crestor came off patent, and the full extent of this patent expiry isn’t yet known. 

According to City consensus, Astra’s top line is expected to fall by 5.8% next year due to management inability to rekindle the company’s pipeline growth. During the third quarter of this year, total product sales were down by 14% at $5bn, as Crestor and Nexium sales declined by 82% and 50% respectively in the US. For the quarter, the company reported a $1bn loss but earnings per share rose 4% to $0.80 thanks to a $453m tax benefit. 

As Astra’s earnings continue to contract with falling sales, it may be wise to avoid the drug maker next year.

Profits evaporate 

Finally, Rolls-Royce (LSE: RR) is a struggling engineer I’m avoiding next year. It has plenty of problems. From falling marine sales as a result of the oil price collapse, to faulty engines delivered to one of its largest customers Emirates, Rolls-Royce is struggling to get things right. What’s more, a new accounting change, whereby the company can’t immediately recognise revenue generated over the life of its engine service contracts immediately, will decimate profitability next year. Under the new accounting rules, Rolls’ 2015 profits would have been £900m lower than the £1.4bn reported. It’s not entirely clear how this change will impact profitability next year, but it’s evident the company will take a big hit to earnings. 

With profits set to tank and problems for the group brewing, Rolls might be one to avoid next year.

Rupert Hargreaves owns shares of Rolls-Royce. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

With stock market risks emerging, is now the time to consider the 60/40 portfolio?

The stock market could be in for a period of turbulence. Here’s a simple strategy that can help long-term investors…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

Is a stock market crash coming? It’s not too late to get ready!

Christopher Ruane sees reasons to fear a coming stock market crash. Rather than tying to time it, he's hoping to…

Read more »

Investing Articles

Down 4% in 2026, is now the time to consider buying Nvidia shares

Has Nvidia become too big to keep growing? Or is the stock’s decline this year a chance to think about…

Read more »

Investing Articles

Is the party finally over for Rolls-Royce shares?

Rolls-Royce shares have made investors rich but momentum is slowing and the Iran conflict isn't helping. How worried should we…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

7.8% dividend yield! A dirt-cheap UK income share to buy today?

I’m on the hunt for lucrative passive income opportunities, and this under-the-radar FTSE stock currently offers a whopping 7.8% dividend…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

3 passive income stocks tipped to soar 41% (or more) by 2027

One of these shares offering passive income is trading at a massive 79% discount to where City analysts think it…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

171,885 shares of this FTSE dividend star pays an income equal to the State Pension

Zaven Boyrazian calculates how many shares investors would have to buy to generate enough income to match the UK State…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

This stock’s the opposite of red-hot at the moment. But I reckon it could still be one to buy

The recent dramatic fall in the value of this FTSE 100 stock makes James Beard think it’s a stock to…

Read more »